セファロスポリン薬のラテンアメリカ・中東・アフリカ市場2019-2025

【英語タイトル】Latin America, Middle East & Africa Cephalosporin Drugs Market (2019-2025)

KBV Researchが出版した調査資料(KBV9DE350)・商品コード:KBV9DE350
・発行会社(調査会社):KBV Research
・発行日:2019年7月
・ページ数:114
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:中南米、中東、アフリカ
・産業分野:産業未分類
◆販売価格オプション(消費税別)
Single User(1名様利用)USD1,500 ⇒換算¥202,500見積依頼/購入/質問フォーム
Site Licence(法人利用)USD2,520 ⇒換算¥340,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The Latin America, Middle East and Africa Cephalosporin Drugs Market would witness market growth of 4.37% CAGR during the forecast period (2019–2025).Antibiotics perform best when a body has a steady level of medication. This is achieved by administering the medicine all day and night at uniformly spaced intervals. The dosage is based on the condition and treatment reaction of a patient. The continued use of this medication until the recommended period is complete is usually suggested, even if the symptoms vanish after a couple of days. Stopping the medication too soon may allow bacteria to continue to develop, leading to an infection recurrence. It is further important to check the item for particles or discoloration visually before use.
Growth in population incidence with pneumonia, tonsillitis, bronchitis, and gonorrhea drives market growth. Over the previous centuries, there are over 50 Cephalosporin Drugs authorized, and nearly half of them are for antibacterial activity. Nevertheless, fresh Cephalosporin Drugss (categorized as the fifth generation) used to treat severe gram-negative bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA), have lately been approved.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Study
Market Segmentation:
By Generation
• First-Generation Cephalosporin
• Second-Generation Cephalosporin
• Third-Generation Cephalosporin
• Fourth-Generation Cephalosporin
• Fifth-Generation Cephalosporin
By Application
• Respiratory Tract Infection
• Skin Infection
• Ear Infection
• Sexually Transmitted Infection
• Others
By Route of Administration
• Injections
• Oral Drugs
By Type
• Branded
• Generic
By Country
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA
Companies Profiled
• ABBOTT Laboratories
• Teva Pharmaceuticals Industries Ltd.
• Johnson and Johnson
• GlaxoSmithKline PLC (GSK)
• Pfizer, Inc.
• Merck & Co., Inc.
• Bayer AG
• Baxter International, Inc.
• BRISTOL-MYERS SQUIBB COMPANY
• Novartis AG
Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Table of Contents: LAMEA Cephalosporin Drugs Market
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Cephalosporin Drugs Market, by Generation
1.4.2 LAMEA Cephalosporin Drugs Market, by Application
1.4.3 LAMEA Cephalosporin Drugs Market, by Route of Administration
1.4.4 LAMEA Cephalosporin Drugs Market, by Type
1.4.5 LAMEA Cephalosporin Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Cephalosporin Drugs Market by Generation
3.1 LAMEA First-Generation Cephalosporin Drugs Market by Country
3.2 LAMEA Second-Generation Cephalosporin Drugs Market by Country
3.3 LAMEA Third-Generation Cephalosporin Drugs Market by Country
3.4 LAMEA Fourth-Generation Cephalosporin Drugs Market by Country
3.5 LAMEA Fifth-Generation Cephalosporin Drugs Market by Country
Chapter 4. LAMEA Cephalosporin Drugs Market by Application
4.1 LAMEA Respiratory Tract Infection Market by Country
4.2 LAMEA Skin Infection Market by Country
4.3 LAMEA Ear Infection Market by Country
4.4 LAMEA Sexually Transmitted Infection Market by Country
4.5 LAMEA Others Market by Country
Chapter 5. LAMEA Cephalosporin Drugs Market by Route of Administration
5.1 LAMEA Injections Market by Country
5.2 LAMEA Oral Drugs Market by Country
Chapter 6. LAMEA Cephalosporin Drugs Market by Type
6.1 LAMEA Branded Market by Country
6.2 LAMEA Generic Market by Country
Chapter 7. LAMEA Cephalosporin Drugs Market by Country
7.1 Brazil Cephalosporin Drugs Market
7.1.1 Brazil Cephalosporin Drugs Market by Generation
7.1.2 Brazil Cephalosporin Drugs Market by Application
7.1.3 Brazil Cephalosporin Drugs Market by Route of Administration
7.1.4 Brazil Cephalosporin Drugs Market by Type
7.2 Argentina Cephalosporin Drugs Market
7.2.1 Argentina Cephalosporin Drugs Market by Generation
7.2.2 Argentina Cephalosporin Drugs Market by Application
7.2.3 Argentina Cephalosporin Drugs Market by Route of Administration
7.2.4 Argentina Cephalosporin Drugs Market by Type
7.3 UAE Cephalosporin Drugs Market
7.3.1 UAE Cephalosporin Drugs Market by Generation
7.3.2 UAE Cephalosporin Drugs Market by Application
7.3.3 UAE Cephalosporin Drugs Market by Route of Administration
7.3.4 UAE Cephalosporin Drugs Market by Type
7.4 Saudi Arabia Cephalosporin Drugs Market
7.4.1 Saudi Arabia Cephalosporin Drugs Market by Generation
7.4.2 Saudi Arabia Cephalosporin Drugs Market by Application
7.4.3 Saudi Arabia Cephalosporin Drugs Market by Route of Administration
7.4.4 Saudi Arabia Cephalosporin Drugs Market by Type
7.5 South Africa Cephalosporin Drugs Market
7.5.1 South Africa Cephalosporin Drugs Market by Generation
7.5.2 South Africa Cephalosporin Drugs Market by Application
7.5.3 South Africa Cephalosporin Drugs Market by Route of Administration
7.5.4 South Africa Cephalosporin Drugs Market by Type
7.6 Nigeria Cephalosporin Drugs Market
7.6.1 Nigeria Cephalosporin Drugs Market by Generation
7.6.2 Nigeria Cephalosporin Drugs Market by Application
7.6.3 Nigeria Cephalosporin Drugs Market by Route of Administration
7.6.4 Nigeria Cephalosporin Drugs Market by Type
7.7 Rest of LAMEA Cephalosporin Drugs Market
7.7.1 Rest of LAMEA Cephalosporin Drugs Market by Generation
7.7.2 Rest of LAMEA Cephalosporin Drugs Market by Application
7.7.3 Rest of LAMEA Cephalosporin Drugs Market by Route of Administration
7.7.4 Rest of LAMEA Cephalosporin Drugs Market by Type
Chapter 8. Company Profiles
8.1 ABBOTT Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.1 Recent strategies and developments:
8.1.1.1 Collaborations, partnerships and agreements:
8.1.1.2 Acquisition and Mergers:
8.2 Teva Pharmaceutical Industries Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product launches:
8.3 Johnson and Johnson
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental &Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 GlaxoSmithKline PLC (GSK)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Collaborations, partnerships and agreements:
8.4.5.2 Expansion:
8.4.5.3 Approval:
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Collaborations, partnerships and agreements:
8.5.5.2 Product launches:
8.5.5.3 Acquisition and Mergers:
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Collaborations, partnerships and agreements:
8.6.5.2 Product launches:
8.7 Bayer AG (Bayer Schering Pharma AG)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Collaborations, partnerships and agreements:
8.7.5.2 Product launches:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Product launches:
8.9 Bristol-Myers Squibb Company
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Collaborations, partnerships and agreements:
8.1 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Product launches:
8.10.5.2 Acquisition and Mergers:



★調査レポート[セファロスポリン薬のラテンアメリカ・中東・アフリカ市場2019-2025] (コード:KBV9DE350)販売に関する免責事項を必ずご確認ください。
★調査レポート[セファロスポリン薬のラテンアメリカ・中東・アフリカ市場2019-2025]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆